<h1 id="toxic-alcohol-ingestion-ethylene-glycol">Toxic Alcohol Ingestion: Ethylene Glycol</h1>
<p>General concepts for all 3 toxic alcohols</p>
<ul>
<li>Parent compounds (not metabolites) cause high osmolal gap</li>
<li>When NAD depleted, pyruvate converts to lactate --&gt; causes lactic acidosis</li>
<li>See metabolism diagram below</li>
</ul>
<h2 id="eg-factoids">EG: Factoids</h2>
<p>Found in antifreeze, coolants, deicing solutions, ink in stamp pads and ballpoint pens
<em>Pharmacology</em>:</p>
<ul>
<li>Peak serum concentration 1-4 hours, elimination half-life 3 hours</li>
<li>Minimum lethal dose 1-1.5 mL/kg </li>
<li>Metabolites (eg. oxalate acid) cause toxicity, but do NOT cause osmolal gap</li>
</ul>
<p><em>Labs:</em> High anion gap metabolic acidosis and high osmolal gap (early only)</p>
<h2 id="eg-classic-presentation">EG: Classic Presentation</h2>
<table>
<colgroup>
<col width="100%" />
</colgroup>
<tbody>
<tr class="odd">
<td><strong>Classic Presentation:<br />
</strong>
<ul>
<li><strong>Altered mental status</strong><br />
</li>
<li><strong>HypoCa</strong><br />
</li>
<li><strong>Oxalate crystals in urine</strong><br />
</li>
</ul></td>
</tr>
</tbody>
</table>

<ul>
<li><strong>Neurologic</strong> – N/V, inebriation with euphoria, nystagmus, ataxia, myoclonic jerks… then CNS depression, hypotonia, seizures, coma</li>
<li><strong>Cardiopulmonary</strong> – Hyperventilation from respiratory compensation of acidosis, hypoxia from heart failure, multiorgan failure, ARDS</li>
<li><strong>Renal</strong> – Flank pain, ATN, renal failure</li>
</ul>
<h2 id="eg-management">EG: Management</h2>
<ul>
<li><strong>Goal:</strong> Prevent further formation of (<span class="drug">fomipezole</span>) &amp; eliminate toxic metabolites (dialysis)</li>
<li><strong>Antidote = <span class="drug">Fomipezole</span></strong> inhibits alcohol dehydrogenase (alternative antidote= ethanol)</li>
<li><strong>Loading dose</strong> 15 mg/kg IV</li>
<li><strong>Maintenance dose</strong> 10 mg/kg IV every 12 hours x 2 days </li>
</ul>
<h2 id="eg-american-academy-of-clinical-toxicology-guidelines">EG: American Academy of Clinical Toxicology guidelines</h2>
<p><strong>Indications for treatment of EG poisoning with ANTIDOTE: (any of following)</strong></p>
<p> Documented plasma ethylene glycol &gt; 20 mg/dL
 Documented recent hx of ingesting toxic EG amounts and osmolal gap &gt; 10 mOsm/L
 Strong suspicion of EG poisoning and at least 2 criteria:</p>
<ol>
<li>Arterial pH &lt; 7.3</li>
<li>Serum bicarbonate &lt; 20 mEq/L</li>
<li>Osmolal gap &gt; 10 mOsm/L</li>
<li>Urine oxalate crystal present</li>
</ol>
<p><strong>Indications for treatment of EG toxicity with HEMODIALYSIS: (any of following)</strong></p>
<ol>
<li>Deteriorating clinical status despite supportive tx PLUS metabolic acidosis (arterial pH &lt; 7.25-7.3)</li>
<li>Acute kidney injury with serum Cr &gt; 3 mg/dL or increase in serum Cr by 1 mg/dL</li>
<li>Acid-base/electrolyte abnormalities unresponsive to standard tx</li>
<li>Old recommendation: EG level &gt; 50 mg/dL</li>
</ol>
<p><em>Note:</em> <span class="drug">Fomipezole</span> without hemodialysis is an option if normal renal function AND no metabolic acidosis</p>
<h2 id="metabolism-of-alcohols">Metabolism of alcohols</h2>
<p><img src="https://d2p53dh3qxfm0x.cloudfront.net/uploads/img/1jx/7/f/b6b37a41-cba1-504b-8372-d4dc376c8e78/640.png" alt=""></p>
<h2 id="references">References</h2>
<ul>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=22261941">Marraffa JM, Cohen V, Howland MA. Antidotes for toxicological emergencies: a practical review. Am J Health Syst Pharm. 2012 Feb 1;69(3):199-212. doi: 10.2146/ajhp110014.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=18045860">Kraut JF, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol. 2008 Jan;3(1):208-25. Epub 2007 Nov 28.</a></li>
<li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=20090509">Jammalamadaka D, Raissi S. Ethylene glycol, methanol and isopropyl alcohol intoxication. Am J Med Sci. 2010 Mar;339(3):276-81. doi: 10.1097/MAJ.0b013e3181c94601.</a></li>
</ul>
